# ADC Therapeutics SA

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ADC Therapeutics SA).

## Overview

ADC Therapeutics SA is a commercial-stage oncology biotechnology company focused on antibody drug conjugates (ADCs). Its marketed product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies, with approvals spanning the U.S. and conditional approvals in Europe, Canada and China. The company combines in-house R&D capabilities with outsourced manufacturing and third-party commercialization infrastructure, while building a pipeline that extends ADC technology into additional hematologic malignancies and solid tumors. Operations are headquartered in Lausanne, Switzerland, with a U.S. presence in New Jersey supporting development and commercialization.

## Products & services

• ZYNLONTA (loncastuximab tesirine-lpyl) for r/r DLBCL
• LOTIS-5 Phase 3: ZYNLONTA + rituximab in earlier-line DLBCL
• LOTIS-7 Phase 1b: ZYNLONTA + bispecific combinations
• Investigator-initiated trials in MZL and follicular lymphoma
• ADC R&D platform (payloads, linkers, conjugation chemistry)
• Greater China/Singapore licensing via Overland ADCT BioPharma JV

- **ZYNLONTA product sales (U.S.)** (80%) — Net product revenue from U.S. sales of ZYNLONTA to wholesalers for use in r/r DLBCL.
- **Ex-U.S. partnered commercialization (Greater China & Singapore)** (10%) — Licensed development and commercialization in China, Hong Kong, Macau, Taiwan and Singapore via Overland ADCT BioPharma, supplied by ADCT at manufacturing cost.
- **Clinical development programs (ZYNLONTA label expansion)** (5%) — Company-sponsored trials such as LOTIS-5 and LOTIS-7 aimed at moving ZYNLONTA into earlier lines and combinations.
- **Early-stage pipeline and platform R&D** (5%) — Discovery/IND-enabling and early clinical work leveraging the ADC platform, including solid-tumor programs such as ADCT-241 (PSMA-targeting).

- ZYNLONTA (loncastuximab tesirine-lpyl) for r/r DLBCL
- LOTIS-5 Phase 3: ZYNLONTA + rituximab in earlier-line DLBCL
- LOTIS-7 Phase 1b: ZYNLONTA + bispecific combinations
- Investigator-initiated trials in MZL and follicular lymphoma
- ADC R&D platform (payloads, linkers, conjugation chemistry)
- Greater China/Singapore licensing via Overland ADCT BioPharma JV

## Customers

In the United States, ADC Therapeutics sells ZYNLONTA through wholesale distributors that resell to hospitals, infusion centers and oncology practices, where the drug is administered to patients with relapsed or refractory DLBCL. Demand is driven by hematologists/oncologists in both academic and community settings, and by payer coverage and treatment pathway placement versus alternatives such as CAR-T, bispecific antibodies and other regimens. The company also engages group purchasing organizations affiliated with community oncology practices, which can influence access and net pricing. Outside the U.S., commercialization in greater China and Singapore is primarily executed by Overland ADCT BioPharma under an exclusive license, with ADCT supplying product and retaining certain global clinical control rights.

- **U.S. oncology providers (academic and community)** (primary) — Use ZYNLONTA for r/r DLBCL patients; adoption depends on clinical profile, pathway placement and reimbursement.
- **U.S. channel intermediaries (wholesalers and distributors)** (primary) — Purchase and distribute ZYNLONTA to provider sites; terms drive inventory levels, fees and gross-to-net adjustments.
- **Payers and government reimbursement programs** (secondary) — Determine net realized price through rebates, chargebacks, fees and policies such as discarded drug rebates.
- **Ex-U.S. partner (Overland ADCT BioPharma)** (secondary) — Develops, seeks regulatory approvals and commercializes in greater China and Singapore; ADCT supplies product at cost and may co-promote via option.

- U.S. wholesale distributors purchasing ZYNLONTA for resale
- Hospitals and cancer centers administering ZYNLONTA infusions
- Community oncology practices influenced by GPO contracting
- Academic hematology/oncology centers using ZYNLONTA in later lines
- Payers/government programs affecting access via rebates/chargebacks
- Overland ADCT BioPharma as ex-U.S. commercialization partner (China/SG)

## Geography

ADC Therapeutics is headquartered in Lausanne (Biopôle), Switzerland, with U.S. operations in New Jersey supporting commercialization and development. Commercial product revenue is generated from ZYNLONTA sales in the United States, where the company directly commercializes through its own field organization and third-party logistics/distribution vendors. In greater China and Singapore, the company operates through a joint venture and license/collaboration with Overland ADCT BioPharma, which is responsible for local development, regulatory approvals and commercialization while ADCT supplies product at manufacturing cost. The geographic footprint matters because regulatory pathways differ across regions (accelerated/conditional approvals), and trade policy changes (tariffs) can affect cost of sales and operating expenses. No authoritative revenue-by-geography percentages were provided in the excerpts, so a quantified regional revenue split is not presented.

- Headquarters in Lausanne (Biopôle), Switzerland
- U.S. operations in New Jersey supporting commercial and R&D activities
- Direct commercialization focus in the United States for ZYNLONTA
- Greater China & Singapore partnered via Overland ADCT BioPharma license/JV
- Regulatory exposure spans FDA, European Commission, NMPA and Health Canada
- Tariffs/trade policy changes can impact cross-border supply chain costs

## Strategy

The company’s near-term strategy centers on maximizing ZYNLONTA by expanding use beyond third-line DLBCL into earlier lines and combination regimens, with LOTIS-5 (rituximab combination) as a confirmatory Phase 3 program and LOTIS-7 exploring bispecific combinations. In parallel, ADC Therapeutics aims to broaden ZYNLONTA’s hematology footprint into indolent lymphomas such as marginal zone lymphoma and follicular lymphoma through investigator-initiated trials at major institutions. For international markets, it is pursuing expansion through direct efforts where feasible and through partnerships such as the Overland ADCT BioPharma arrangement in greater China and Singapore. Longer term, the company is advancing its ADC platform into solid tumors and evaluating partnering options for programs such as ADCT-241 (PSMA-targeting, exatecan-based), balancing capital needs with pipeline optionality.

- **Confirm and expand ZYNLONTA in DLBCL** (medium-term) — Earlier-line and combination use increases addressable patients and supports durable approvals.
- **Broaden hematology indications beyond DLBCL** (medium-term) — Indolent lymphoma expansion can diversify demand while leveraging the same commercial channel.
- **Advance and partner the solid-tumor ADC portfolio** (long-term) — Solid tumors expand long-term optionality but may require partnerships to fund development and commercialization.

- Expand ZYNLONTA into earlier-line DLBCL via LOTIS-5 confirmatory Phase 3
- Develop combination regimens (e.g., bispecific combos in LOTIS-7)
- Extend into indolent lymphomas via investigator-initiated trials (MZL, FL)
- Scale ex-U.S. reach through partnerships (Overland in China/SG)
- Leverage ADC platform (payloads/linkers/conjugation) for next-gen candidates
- Seek partnering opportunities for solid-tumor pipeline (e.g., ADCT-241)

## Risks

ADC Therapeutics’ business is highly dependent on ZYNLONTA, so any slowdown in adoption, competitive displacement (e.g., CAR-T, bispecific antibodies, other ADCs) or safety/tolerability issues could materially affect revenue and cash runway. Clinical and regulatory execution risk is significant: confirmatory and expansion trials may not read out as expected or on planned timelines, and accelerated/conditional approvals can be vulnerable if confirmatory evidence is insufficient. The company also faces financing and balance-sheet risks, including the need for additional capital, restrictive debt covenants, and the HCR royalty purchase agreement that reduces cash retained from ZYNLONTA sales and can change based on sales performance and milestones. Operationally, reliance on third parties for logistics, distribution and manufacturing/supply to partners introduces supply continuity and compliance risk, while changes in tariffs and trade policies can raise costs. Like other biopharma companies, it is exposed to cybersecurity, intellectual property disputes, and rapid technological change in the ADC field.

- **Need for additional capital and continued losses** [high] — The company expects to continue incurring losses and may need to raise capital to fund operations and execute its plan.
- **HCR royalty purchase agreement reduces cash generation from ZYNLONTA** [high] — Cash retained from ZYNLONTA sales/licensing is reduced and the obligation can vary with sales milestones and change-of-control timing.
- **Clinical trial timing and outcome uncertainty** [high] — Ongoing/planned trials may not complete on expected timelines or produce sufficient results to support approvals/label expansion.
- **Tariffs and trade policy changes** [medium] — Changes in tariffs/trade policies could increase cost of sales and operating expenses, impacting margins and cash burn.
- **Product safety and adverse events** [high] — Undesirable side effects could reduce physician adoption, lead to warnings/restrictions, or increase post-marketing obligations.

- Concentration risk: ZYNLONTA is the primary commercial product
- Clinical trial failure/delay risk for LOTIS-5/LOTIS-7 and other studies
- Competitive pressure from CAR-T, bispecific antibodies and other ADCs
- Safety/adverse events could limit use or trigger label restrictions
- Need for additional capital; ongoing losses may persist
- Debt covenants and HCR royalty obligation reduce financial flexibility
- Tariffs/trade policy changes may increase cost of sales/opex
- Third-party dependencies (3PL, distributors, vendors) and cyber risk

## Accounting

Reported ZYNLONTA revenue is recognized when control transfers to the customer, but the net amount is heavily influenced by gross-to-net (GTN) estimates for rebates, chargebacks, distributor service fees, returns/allowances and discounts. These GTN adjustments require significant judgment, including reliance on third-party channel and prescription data that can arrive with lags and may itself be estimated, creating potential quarter-to-quarter volatility as accruals are trued up. A notable estimate area is the discarded drug rebate, which can create material cash payments and affect revenue reserves. Interest expense and related balance sheet presentation are also sensitive to estimates because the HCR deferred royalty obligation accretes based on projected net sales and milestone assumptions, so changes in sales outlook can affect the effective rate and carrying amounts. Investors should also consider the accounting impact of collaboration arrangements (e.g., supply at manufacturing cost and cost-sharing terms) on reported margins and operating expenses.

- **Product revenues, net (gross-to-net adjustments)** — Revenue, accounts receivable/contra-revenue reserves, period-to-period volatility
- **Discarded drug rebate estimation** — Contra-revenue reserves and operating cash flow timing
- **Deferred royalty obligation (HCR) and accretion** — Interest expense and carrying value of the royalty obligation

- Net product revenue depends on GTN estimates (rebates, chargebacks, fees)
- Returns/allowances and channel inventory affect revenue timing/volatility
- Discarded drug rebate requires substantial judgment and impacts accruals
- Third-party data lags can cause periodic true-ups to GTN reserves
- HCR deferred royalty obligation accretion depends on sales projections
- Interest expense reflects both term loan and HCR accretion mechanics
- Collaboration supply-at-cost terms can affect reported gross margin

---

*Last updated: 2026-08-11T04:46:17.097297+00:00*